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Abstract 
 
Background: Proton pump inhibitors (PPIs) decrease the rate of rebleeding following endoscopic hemostatic 
therapy in patients with bleeding peptic ulcers. This study compares the efficacy of oral omeprazole vs intrave-
nous pantoprazole in decrease of rebleeding of peptic ulcer patients.  
 
Methods: One hundred and six patients with high risk peptic ulcer were randomized to receive either oral 
omeprazole (80 mg BID for 3 days) or IV pantoprazole (80 mg bolus and 8 mg/hour infusion for 3 days) followed 
by omeprazole (20 mg each day for 30 days). All patients underwent upper endoscopy and endoscopic therapy 
within 24 hours.  
 
Results: Seventeen patients were excluded from the study. Forty four patients were randomly allocated into 
omeprazole group and 41 patients to IV pantoprazole group. Both groups were similar for factors affecting the 
outcome. Bleeding reoccurred in five patients of omeprazole group and four patients in pantoprazole group 
(11.4% vs 9.8 %). The mean hospital stay and blood transfusion were not different in both groups.  
 
Conclusion: Oral omeprazole and IV pantoprazole had equal effects on prevention of rebleeding after endo-
scopic therapy in patients with high risk bleeding peptic ulcers. 
IRCT ID: IRCT138711191650N1 
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Introduction 
 
Upper gastrointestinal bleeding is a common emer-
gency with significant morbidity and mortality. Peptic 
ulcer disease is the most common cause accounting 
for about 50% of episodes.
1,2 Endoscopic therapy of 
high risk ulcers such as epinephrine injection reduces 
rebleeding, morbidity and even mortality.
3,4 There-
fore, it is currently recommended as the first line of 
hemostatic intervention for these patients.
4,5 However, 
high risk ulcers rebleed in 14-36% of patient in spite 
of efficient endoscopic intervention.
5,6 Gastric acid 
inhibits clot formation and promotes clot lyses and 
therefore disturbs hemostasis of ulcers in the stomach 
and duodenum. So reduction of gastric acid secretion 
could prevent ulcer rebleeding.
7  
Several controlled trials and meta-analysis studies 
have shown the efficacy of intravenous and oral pro-
ton pump inhibitors (PPIs) in high risk bleeding ul-
cers after endoscopic therapy.
8-16 The comparable ef-
fectiveness of oral (PO) and intravenous (IV) route of 
administration is not well known; therefore a few 
cost-effectiveness studies were designed, but they 
show conflicting results and were not conclusive.
17-20 
So to reduce health cost, head to head comparison of 
these two routes is necessary.  
Comparing oral and IV administration of PPI in 
bleeding peptic ulcers has been studied by Bajaj et 
al.,
21 and Tsai et al.,
22 however, some problems were 
encountered in both studies. Bajaj et al. has done a 
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pilot study with small number of patients and Tsai et 
al. has used regular dose and not high dose of PPI.
21,22  
In order to achieve a better evaluation, a prospective, 
randomized controlled trial was designed to compare 
oral and intravenous high dose of PPI in high risk 
peptic ulcer bleeding after endoscopic intervention. 
 
 
Materials and Methods  
 
The protocol was approved by the Ethic Committee 
of Research Department of Shiraz University of Med-
ical Sciences (SUMS) and a written informed consent 
was obtained from all subjects. From November 2008 
to July 2009, all adult patients who were admitted to 
medical emergency rooms of Faghihi and Nemazee 
hospitals affiliated to SUMS due to upper gastrointes-
tinal bleeding (as evidenced by hematemesis, melena 
or hematochezia) were considered for inclusion in the 
study.  
Endoscopy was performed within 24 hours after 
admission. Patients older than 18 years with success-
ful endoscopic therapy of high risk ulcers [defined as 
active bleeding (Forrest IA, IB), non- bleeding visible 
vessel (NBVV, Forrest IIA) or adherent clots (Forrest 
IIB)] were enrolled. Patients with low risk ulcers 
(clean base, ulcers with a simple washable clot), sus-
picious malignant ulcer, bleeding tendency, uremia, 
liver cirrhosis, Mallory Weiss tear or already on PPI 
as an outpatient were excluded from study.  
The patients with high risk peptic ulcer (Forrest 
IA-IIB) were managed endoscopically by injecting 5-
30  ml of epinephrine (diluted 1:10000) around the 
ulcer crater to stop bleeding. Cavitation or flattening 
of bleeding vessel and disappearance of NBVV was 
considered as established homeostasis. Thereafter, an  
electrocoagulation therapy by Argon Plasma Coagu-
lation (APC) was applied in some patients with active 
bleeding and NBVV for further hemostasis.  
A biopsy was taken from antrum for evaluating H. 
pylori infection. Patient with unsuccessful endoscopic 
therapy were not enrolled and such patients consulted 
immediately with a general surgeon. A questionnaire 
(including information on demography, history of 
previous upper gastrointestinal bleeding, NSAID or 
ASA ingestion, ulcer location, bleeding stigmata and 
blood transfusion volume at entry) was completed for 
all high risk patients. 
All the enrolled patients were allocated into two 
groups to receive either oral omeprazole or IV panto-
prazole based on even and odd days of the month. In 
the omeprazole (OMP) group, the patients received 40 
mg omeprazole (Roozdaru Pharmaceutical Co., Teh-
ran, Iran) orally twice daily for 72 hours. In pantopra-
zole (PAN) group, patients received pantoprazol (NY-
COMED Pharmaceutical Co., Germany) 80 mg bolus 
and then 8 mg/hour infusion for 48-72 hours. Then, all 
patients received omeprazole, 20 mg orally for 30 
days. On the day of discharge H. pylori infected pa-
tients were treated using standard regimens.  
The patients were monitored for supine and sit-
ting vital signs (BP, PR), intravenous fluid intake, 
blood transfusion and urine output. Hemoglobin 
(Hb) was checked every each 8 hours and blood 
transfusion was done if Hb was lower than 8 g/dl or 
the patient was in the state of shock. Rebleeding was 
suspected if persistent tarry stool, reappearance of 
hematemesis, orthostatic hypotension, unstable vital 
sign (BP≤90, PR≥120) or Hb drop≥2 g.dl, (despite 
blood transfusion) developed after the first endo-
scopic therapy. Patients suspected to rebleeding 
were evaluated by urgent endoscopy and if active 
bleeding, fresh blood or blood clots were seen, re-
bleeding was documented. In such cases, endoscopic 
therapy with epinephrine injection and electrocoagu-
lation (by Argon plasma coagulation, APC) was 
done to stop bleeding.  
Statistical analysis was performed using statistical 
analysis of SPSS software (Version 11.5, Chicago, Il, 
USA). The descriptive variables such as mean, stand-
ard deviations and frequency were used. Chi Square 
(X
2) was performed for finding out the association 
between rebleeding, blood transfusion, reendoscopy 
and OPM or PAN groups. T-test was performed to 
difference between hospital stay, amount of blood 
transfusion and OPM or PAN groups. P value less 
than 0.05 was considered significant.   
 
 
Results  
 
From 209 patients who were referred to Emergency 
Room due to upper GI bleeding, 102 patients had 
high risk peptic ulcer in endoscopic evaluation. Sev-
enteen patients were excluded from the study (bleed-
ing tendency=4, uremia=2, gastric cancer=3, Mallo-
ry Weiss tear=1, esophageal varices=4, primary en-
doscopic failure=3). Finally, 85 patients completed 
the study (44 patients in OMP group and 41 patients 
in PAN group). Both groups were similar in source 
of bleeding and factors affecting the outcomes (Ta-
ble 1).  Mostaghni et al. 
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Five patients in OMP group and 4 in the PAN group 
rebled (11.4% vs 9.8%) which was not statistically sig-
nificant (p=0.810) (Table 2). From the 5 rebleeding cas-
es in OMP group, 3 patients rebled in hospital course 
and were successfully managed by endoscopic epineph-
rine injection and electrocoagulation (APC). Then, 
bleeding did not reoccur up to 2 wk follow up. In 2 pa-
tients, bleeding developed in 2 weeks after discharge 
during the follow up. They were managed again with 
epinephrine injection and APC and bleeding did not 
reoccur up to 2 weeks after the follow up.  
In PAN group, 4 patients rebled, two of them oc-
curred in hospital course and stopped with epineph-
rine injection plus APC and recovered uneventfully. 
The two other patients rebled in follow up period and 
bleeding stopped with sclerotherapy and APC. Bleed-
ing did not reoccur up to 2 weeks but in one patient 3 
weeks later, bleeding reoccurred (5 weeks after index 
bleeding). So, surgical intervention was done because 
bleeding continued and endoscopic therapy failed. 
One patient in each group died which was due to a 
comorbid disease and not bleeding. The number of 
blood transfusion and hospital stay were not statisti-
cally different in both groups (Table 2). In none of 
cases, surgical intervention was done for control of 
bleeding after endoscopic therapy (except for one pa-
tient whose surgery was done 5 weeks after the index 
bleeding and 3 patients who were operated due to 
failure of primary endoscopic hemostatic therapy).  
The cost of oral and intravenous administration of 
drugs was calculated, being significantly lower in the 
OMP group than PAN group (Table 3). Moreover, the 
mean of the hospital stay in both groups was not sta-
tistically different (Table 2) and oral administration of 
omeprazole led to less hospital stay and costs. 
 
 
Discussion  
 
Endoscopic therapy decreases but does not eliminates 
the risk of adverse outcome in peptic ulcer bleed-
ing.
5,6 On the other hand, gastric acid antagonizes 
Table 1: Demographic and presentation characteristics of 89 studied patients
       OMP group (no.= 44) PAN group (no.=41) 
Gender (male/Female)  33/11  30/11 
Age (years) (mean ±SD)  57.25±16.45  61.66±17.17 
NSAID, ASA use (%)   19 (43)  17 (41) 
Ulcer Location      
Gastric (%)  24 (54)  18 (44) 
Duodenal (%)  17 (39 )  20 (49) 
Both (%)  3 (7 )  3 (7) 
Ulcer stigmata     
Adherent clot (%)  5 (11)  3 (7) 
Visible Vessel (%)  25 (57)   26 (63) 
Blood oozing (%)  8 (18)  5 (13) 
Active Bleeding (%)  6 (14)  7 (17) 
Therapeutic intervention     
Epinephrine injection alone (%)  29 (66)  28 (68) 
Epinephrine + APC (%)  14 (32)  12 (29.5) 
Epinephrine + endoclips (%)  1 (2)  1 (2.5) 
Table 2: Primary and secondary end points
a 
  OMP group
(no.= 44) 
PAN group 
(no.=41) 
P value
Rebleeding (%)  5 (11.4)  4 (9.8)  0.810 
Surgery (%) 0  (0) 0 (0) N.S. 
Death (%)  1 (2)  1 (2)  N.S. 
Hospital stay (Day)  3.1  3.6  0.130 
Blood transfusion (%) 31  (71) 33 (81) 0.284 
Amount of blood Transfusion (bag)  1.82  1.95  0.641 
Reendoscopy (%)  18 (41)  24(59)  0.104 
a N.S: statistically not significant PPIs in peptic ulcer 
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hemostasis in the stomach and duodenum by impair-
ing clot formation and promoting clot lysis.
7 So, 
maintenance of intragastric pH>6 has been consid-
ered to result in a lower rebleeding rate of peptic ul-
cer. In recent years, several studies have shown the 
efficacy of IV proton pump inhibitors (PPIs) in reduc-
ing the adverse outcome of peptic ulcer bleeding, de-
spite the optimal dose, and the best route of admin-
istration has remained controversial.
11,12,23 However, 
IV administration of PPIs has limitations. They are 
expensive, require a dedicated IV line, need nursing 
supervision and hospital admission. So, it would be 
reasonable to prescribe oral PPIs to patients with high 
risk bleeding ulcers provided that it is as effective as 
its IV counterpart.  
Oral PPIs have a high bioavailability. Its effect ini-
tiates one hour after ingestion and the maximal plas-
ma concentration is achieved after 2-3 hours.
24 Sever-
al studies have shown similar effectiveness of oral 
and IV PPIs on rising intragastric pH. Laine et al. in 
their study comparing frequent oral and IV lanzopia-
zole have shown that intragastric pH differs only at 
the first hour of administration and at >1.5 hour, there 
is no difference among all hourly intragastric pH be-
tween both groups.
25 More recently, Javid et al. have 
demonstrated that IV and high PO doses of various 
PPIs are equal in their ability to suppress gastric acid 
secretion and there is no significant difference among 
various PPIs given through different routes on rising 
gastric pH above 6 for 72 hours after successful endo-
scopic hemostasis.
26 
In the clinical setting, many studies have shown 
that oral PPIs are effective in decreasing the adverse 
outcomes of high risk bleeding ulcers especially re-
bleedings.
13-16 It seems that oral PPI is not less effec-
tive than IV PPI. Bardou et al. in their meta-analysis 
study have concluded that high dose oral PPI follow-
ing endoscopic treatment significantly decreases re-
bleeding (-15.3%; 95% CI: -16.5 to -14.0) and proba-
bly mortality as compared with placebo.
12  
Andriulli  et al. in summarization of several 
randomized trials have concluded that PPI decreases 
the adverse outcome of ulcer bleeding independent of 
the route and dose of PPI.
27 Moreover Leontiadis et 
al. recently showed that administering oral PPI both 
before and after endoscopic hemostatic therapy for 
patients with high risk ulcer bleeding is likely to be 
the most cost-effective strategy.
19   
However there are few studies comparing oral and 
IV PPI head to head in clinical setting so for. To the 
best of our knowledge, only recently Tsai et al. in a 
randomized control head to head trials comparing oral 
rabeprazole and IV omeprazole, concluded that both 
forms of PPI prevented equally rebleeding in patients 
with high risk peptic ulcers.
22 However in Tsai et al.´s 
study a high dose of oral PPI has been compared with 
regular dose of IV PPI (40 mg IV infusion each 12 
hours) and not high dose of PPI which is believed 
(despite controversial results) to be more effective. 
Therefore there was an attempt in this study to com-
pare oral and IV PPI directly. 
Our study revealed that high dose oral omeprazole 
(40 mg bid) is equally effective as high dose IV pan-
toprazole (8 mg each hour) in recurrent bleeding, 
blood transfusion hospital study and mortality after 
successful endoscopic hemostatic therapy. In compar-
ison with Tsai et al.'s study we achieved a lower rate 
of rebleeding (overall 10.6% vs. 16%) similar to re-
sult obtained by Colvet et al.
28 which could be due to 
combination endoscopic therapy done as a primary 
hemostatic procedure. (In 34% of patient combination 
therapy applied). However our rebleeding rate was 
higher than that in Lau et al.'s study (10.6 % vs. 6.7%).  
Our patients had a high rate of ASA and NSAID 
consumption (overall 42%) and this may result in 
higher bleeding rate. But it could be concluded that 
oral PPIs are also effective in patients who are on 
ASA or NSAIDS and develop ulcer bleeding. Also, our 
study revealed that oral administration of PPI drugs are 
more economical and cost effective than IV administra-
tion route. Furthermore, using oral route will decrease 
personal, pharmaceutical and medical care costs.  
Table 3: The cost of oral oral omeprazole and intravenous pantoprazole administration in each patient 
  PAN group OMP group 
Nursing care (Rials)  22,850  2,300 
Equipments (Rials)  17,800  - 
Drug:    
Stat dose
a(Rials) 300,000  - 
Maintenance for 24 h (Rials)  820,000 
b 3,000 
c 
Total (Rials)  1,160,650  5,300 
aStat dose 80 mg pantoprazole, 
bEight mg each hour, 
cForty mg each 12 hours Mostaghni et al. 
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Several limitations could be considered in our 
study. First we administered the drugs on admission 
and before the endoscopic therapy. Considering the 
fact that the presence of blood in stomach causes pro-
ton pumps activation and their subsequent irreversible 
deactivation by PPIs, we administered PPI (both oral 
and IV) on admission and before endoscopic interven-
tion. Currently available evidences have shown that 
preendoscopic administration of PPIs in patients with 
non-variceal upper gastrointestinal bleeding downstag-
es the severity of the endoscopic signs of recent bleed-
ing and may reduce the requirement for endoscopic 
hemostatic therapy at index endoscopy although it does 
not affect the mortality, rebleeding or surgical inter-
vention rates.
19,23 However our results showed that 
preendoscopic administration of PPIs affect the ad-
verse outcome in patients with peptic ulcer bleeding.  
Second we did not calculate the Rockall score to 
determine if both groups have equal risk of rebleed-
ing. Still, both groups were matched for factors af-
fecting the adverse outcome. Third we imposed strict 
exclusion criteria on various factors, so a large num-
ber of patients dropped, resulting in the fact that the 
merit of our study was low for detecting small differ-
ences. However surgical intervention and mortality 
rate is very low in peptic ulcer bleeding due to ad-
vanced therapeutic methods applied in recent years 
and for evaluation of such subtle differences a very 
large number of patients should be evaluated. 
In conclusion, our study revealed that oral high 
dose PPI is as effective as IV high dose PPI in reduc-
ing rebleeding rate, mortality, hospital stay, and blood 
transfusion after endoscopic therapy of patients who 
bleed from peptic ulcers and it will be possible to be 
replaced with IV PPI although further similar studies 
are recommended to support the result of this study. 
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